ly3298176 tirzepatide Demonstrates 94% Diabetes Reduction, 22% Weight Loss in SURMOUNT-1 Study LY3298176, a novel dual GIP

The FDA has approved three GLP-1s in particular for both type 2 diabetes treatment and weight loss: Liraglutide (Saxenda, Victoza): While effective, this once-daily injection generally leads to more modest weight loss compared to newer options (its been around since 2014)

Until you know how the medications side effects affect your training, you should increase mileage more gradually than usual

What the clinical data actually says The prescribing information for semaglutide acknowledges the potential for altered absorption of oral medications due to delayed gastric emptying

GLP-1s are effective for weight loss, and at lower doses combined with ongoing support, theyre more sustainable